Canada - English - Health Canada

teva canada limited - galantamine (galantamine hydrobromide) - capsule (extended release) - 24mg - galantamine (galantamine hydrobromide) 24mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

pro doc limitee - galantamine (galantamine hydrobromide) - capsule (extended release) - 8mg - galantamine (galantamine hydrobromide) 8mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

pro doc limitee - galantamine (galantamine hydrobromide) - capsule (extended release) - 16mg - galantamine (galantamine hydrobromide) 16mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

pro doc limitee - galantamine (galantamine hydrobromide) - capsule (extended release) - 24mg - galantamine (galantamine hydrobromide) 24mg - parasympathomemetic (cholinergic) agents

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - galantamine hydrobromide, quantity: 30.76 mg (equivalent: galantamine, qty 24 mg); galantamine, quantity: 24 mg (equivalent: galantamine hydrobromide, qty 30.76 mg) - capsule, modified release - excipient ingredients: ethylcellulose; hypromellose; diethyl phthalate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; potassium hydroxide; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate; macrogol 400; maize starch; sucrose - indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - galantamine hydrobromide, quantity: 20.51 mg (equivalent: galantamine, qty 16 mg); galantamine, quantity: 16 mg (equivalent: galantamine hydrobromide, qty 20.51 mg) - capsule, modified release - excipient ingredients: diethyl phthalate; ethylcellulose; hypromellose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch; sucrose; macrogol 400; titanium dioxide; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate; ethanol absolute; sulfuric acid - indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - galantamine hydrobromide, quantity: 10.25 mg (equivalent: galantamine, qty 8 mg); galantamine, quantity: 8 mg (equivalent: galantamine hydrobromide, qty 10.25 mg) - capsule, modified release - excipient ingredients: hypromellose; diethyl phthalate; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; maize starch; sucrose; macrogol 400; titanium dioxide; sorbitan monolaurate; gelatin; sodium lauryl sulfate; potassium hydroxide - indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 8 mg - galantamine extended-release capsules are indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine extended-release capsules are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of galantamine extended-release capsules in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically (see data) . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data in rats,

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - galantamine hydrobromide, quantity: 30.768 mg - capsule, modified release - excipient ingredients: magnesium stearate; titanium dioxide; hydrogenated vegetable oil; gelatin; iron oxide red; brilliant blue fcf; povidone; sunset yellow fcf; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; colloidal anhydrous silica; sodium lauryl sulfate; polyvinyl acetate

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - galantamine hydrobromide, quantity: 20.512 mg - capsule, modified release - excipient ingredients: gelatin; allura red ac aluminium lake; hydrogenated vegetable oil; titanium dioxide; magnesium stearate; povidone; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; colloidal anhydrous silica; sodium lauryl sulfate; polyvinyl acetate